Exchange: NYSE·Updated 07:15 PM EDT
A logo

AAgilent Technologies Inc.

$132.83
$0.255
(0.19%)
Today
Closed $132.83
$0.94
(0.71%)
After Hours
EarningsAug 26
Mkt Cap$37.52B
Vol2.02M
News
all
press releases
Why Is Agilent (A) Up 0.1% Since Last Earnings Report?
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
More News
News Placeholder
Agilent Technologies, Inc. (A) Initiated at Neutral With $150 Price Target by Piper Sandler
Agilent Technologies, Inc. (A) Initiated at Neutral With $150 Price Target by Piper Sandler...
Yahoo! Finance: News
News Placeholder
Agilent Completes Acquisition of Biocare Medical
Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction...
Business Wire
News Placeholder
Is the Options Market Predicting a Spike in Agilent Technologies Stock?
Investors need to pay close attention to A stock based on the movements in the options market lately.
Zacks
News Placeholder
Strength in Technology Enabled Products Drives Roper: Can the Momentum Sustain?
ROP's Technology Enabled Products segment is benefiting from medical product demand, helping support its 2026 growth outlook.
Zacks
News Placeholder
Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the companys products, operations, and customer workflows. AI is a top priority, and this partnership reflects both...
Business Wire
News Placeholder
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma...
Business Wire
News Placeholder
Agilent (A) Reliance on International Sales: What Investors Need to Know
Examine Agilent's (A) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Zacks
News Placeholder
Agilent Q2 Earnings Call Shows Ignite Driving a Higher Outlook
A beat Q2 estimates and raised its fiscal 2026 outlook. It says its Ignite operating system is driving more durable gains in pricing, execution and margins.
Zacks
News Placeholder
Why Agilent Technologies Stock Triumphed on Thursday
Key PointsThe healthcare solutions specialist is also on track to top analyst estimates for the full year...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.